Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The dengue virus (DENV) NS5 protein plays a central role in dengue viral RNA synthesis which makes it an attractive target for antiviral drug development. DENV NS5 is known to interact with the stem-loop A (SLA) promoter at the 5'-untranslated region (5'-UTR) of the viral genome as a molecular recognition signature for the initiation of negative strand synthesis at the 3' end of the viral genome. However, the conformational dynamics involved in these interactions are yet to be fully elucidated. Our study explores the structural dynamics of NS5 from DENV serotype 2 (DENV2 NS5) in complex with SLA, employing surface plasmon resonance (SPR), hydrogen - deuterium exchange coupled to mass spectrometry (HDX-MS), computational modeling, and cryoEM single particle analysis to delineate the molecular details of their interaction. Our findings indicate that DENV2 NS5 binds SLA in a closed conformation with significant interdomain cooperation between the methyltransferase (MTase) and RNA-dependent RNA polymerase (RdRp) domains, a feature integral to the interaction. Our HDX-MS studies reveal SLA-induced conformational changes in both domains of DENV2 NS5, reflecting a potential mechanism for dengue NS5's multifunctional role in viral replication. Lastly, our cryoEM structure provides the first visualization of the DENV2 NS5-SLA complex, confirming a conserved SLA binding mode across DENV serotypes. These insights obtained from our study enhance our understanding of dengue NS5's complex conformational landscape, supporting the potential development of antiviral strategies targeting dengue NS5's conformational states.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11642867PMC
http://dx.doi.org/10.1101/2024.12.03.626708DOI Listing

Publication Analysis

Top Keywords

denv2 ns5
12
dengue ns5's
12
structural dynamics
8
dengue virus
8
denv ns5
8
viral genome
8
ns5
7
dengue
6
sla
5
dynamics dengue
4

Similar Publications

Widespread yellow fever virus (YFV) immunity in Sub-Saharan Africa may mitigate orthoflavivirus outbreaks. Here, we investigate whether pre-existing YFV-17D immunity confers cross-protection against dengue virus serotype 2 (DENV-2) infection in a murine model. IFNAR1 mice immunized with YFV-17D exhibited significantly reduced DENV-2 viremia, weight loss, and disease severity, with improved survival compared to naïve controls.

View Article and Find Full Text PDF

Genomic evidence links human dengue cases with undetermined serotypes to sylvatic lineages.

Trop Med Health

August 2025

Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Selangor, Malaysia.

Background: Sylvatic dengue viruses, typically maintained in non-human primate and forest mosquito cycles, have rarely been associated with human infections. However, sporadic spillovers have been reported in Southeast Asia, including Malaysia. These events are often under-detected due to the genetic divergence of sylvatic strains from endemic urban dengue viruses.

View Article and Find Full Text PDF

Dengue virus (DENV) has emerged as a formidable global health challenge, with a surging incidence rate across the world. Despite numerous research initiatives aimed at developing effective antiviral therapy, no clinically proven drug or vaccine has been identified to combat all four genetically diverse serotypes of DENV. Therefore, comparative analysis of repurposed drugs and phytocompounds against all DENV serotypes is critical in the search for an effective long-term solution to this menacing disease.

View Article and Find Full Text PDF

Identifying hypaphorine as a novel antiviral compound against dengue virus.

Antiviral Res

August 2025

Department of Pathogen Biology, School of Public Health, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address:

Approximately 390 million individuals globally are infected with dengue virus annually. Notably, no specific therapeutic strategy has been clinically approved for dengue fever to date. In this study, molecular docking screening against the methyltransferase (MTase) domain of the dengue virus (DENV) NS5 protein unveiled hypaphorine as a high-affinity ligand, with calculated binding energies of -6.

View Article and Find Full Text PDF

Inter-host diversity associated with age, sex, and menstrual cycle modulates clinical manifestations in DENV-2 patients.

iScience

May 2025

Division of Immunology and Infectious Disease Biology, INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, New Delhi, Delhi 110007, India.

Dengue virus (DENV-2) remains a global threat, yet the influence of age, sex, and menstrual status on its epidemiology and genetic diversity is underexplored. We analyzed 2136 hospitalized DENV-2 patients (ages 0-86) using whole-genome sequencing (WGS) to examine how these host factors shape interhost viral diversity and clinical manifestations. Young adult males (19-35 years) had the highest prevalence with sex-based clinical differences where females exhibited severe hematological changes, while males showed increased hepatic injury.

View Article and Find Full Text PDF